Hoehn J L, Plotka E D, Dickson K B
Ann Surg. 1979 Jul;190(1):69-71. doi: 10.1097/00000658-197907000-00015.
The estrogen receptor (ER) level in carcinoma of the breast is a useful predictor of response to hormonal therapy. Metastatic disease may not have the same level of ER as the primary. In a series of 37 patients who had simultaneous ER determination in both primary neoplasm and regional nodal metastasis there was 81% agreement. The true ER character of the tumor would have been missed in seven patients if only the primary tumor had been sampled. The possible reasons for this discrepancy are discussed. We feel that the nodal metastatic deposit may reflect the true nature of the ER status because it represents a purer concentration of tumor cells as well as representing the aggressive element of the tumor.
乳腺癌中的雌激素受体(ER)水平是激素治疗反应的有用预测指标。转移性疾病的ER水平可能与原发性疾病不同。在一组37例同时对原发性肿瘤和区域淋巴结转移进行ER测定的患者中,符合率为81%。如果仅对原发性肿瘤进行取样,7例患者的肿瘤真实ER特征将会被遗漏。本文讨论了这种差异的可能原因。我们认为,淋巴结转移灶可能反映了ER状态的真实性质,因为它代表了更纯粹的肿瘤细胞集中情况,也代表了肿瘤的侵袭性成分。